Forxiga (dapagliflozin) ( DrugBank: Dapagliflozin )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
86肺動脈性肺高血圧症1
88慢性血栓塞栓性肺高血圧症1

86. 肺動脈性肺高血圧症


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-006787-25-DK
(EUCTR)
06/07/202222/12/2021The effects of dapagliflozin in patients with elevated blood pressure in the lungsEffects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension
MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 21.1;Classification code 10065151;Term: Idiopathic pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 24.1;Classification code 10085244;Term: Heritable pulmonary arterial hypertension;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 21.0;Classification code 10068740;Term: CTEPH;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Forxiga (dapagliflozin)
Product Name: Forxiga
INN or Proposed INN: Dapagliflozin
Rigshospitalet The Heart CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
52Phase 2Denmark

88. 慢性血栓塞栓性肺高血圧症


臨床試験数 : 157 薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-006787-25-DK
(EUCTR)
06/07/202222/12/2021The effects of dapagliflozin in patients with elevated blood pressure in the lungsEffects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension
MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 20.0;Level: LLT;Classification code 10065150;Term: Associated with pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 21.1;Classification code 10065151;Term: Idiopathic pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 24.1;Classification code 10085244;Term: Heritable pulmonary arterial hypertension;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 21.0;Classification code 10068740;Term: CTEPH;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Forxiga (dapagliflozin)
Product Name: Forxiga
INN or Proposed INN: Dapagliflozin
Rigshospitalet The Heart CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
52Phase 2Denmark